Clinical trial · Observational
Liquid Biopsy in Lung Cancer
Clinical Utility of Combined CTC and ctDNA Assay in the Diagnosis of Primary Lung Cancer
NCT03479099CI-TRIAL-00040251completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to assess clinical utility of combined circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) in the diagnosis of primary lung cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Circulating Tumor Cell | — | UNRESOLVED | — |
| Lung Cancer (Diagnosis) | Malignant Lung Neoplasm | CURATED_EXACT | 0.85 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Diagnostic sensitivity of combined CTC and ctDNA
- timeFrame
- 1 year
- description
- To compared the sensitivity of combined CTC and ctDNA with those of CTC and ctDNA alone in diagnosis of primary lung cancer
Secondary outcomes (2)
- measure
- Diagnostic accuracy of combined CTC and ctDNA
- timeFrame
- 1 year
- description
- To compared the accuracy of combined CTC and ctDNA with those of CTC and ctDNA alone in diagnosis of primary lung cancer
- measure
- Diagnostic specificity of CTC and ctDNA
- timeFrame
- 1 year
- description
- To compared the specificity of combined CTC and ctDNA with those of CTC and ctDNA alone in diagnosis of primary lung cancer
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histology-proven lung cancer or a clinical suspicion of lung cancer * Age \>=18, \< 80 years * No previous history of cancer treatment within 5 years * Patients who agree to participate Exclusion Criteria: * Patients who have been diagnosed with malignancy within 5 years * Patients with previous history of lung cancer * Patients who have uncontrolled coagulopathy
References
Publications (1)
- DERIVEDMoon SM, Kim JH, Kim SK, Kim S, Kwon HJ, Bae JS, Lee S, Lee HS, Choi MY, Jeon BH, Jeong BH, Lee K, Kim HK, Kim J, Um SW. Clinical Utility of Combined Circulating Tumor Cell and Circulating Tumor DNA Assays for Diagnosis of Primary Lung Cancer. Anticancer Res. 2020 Jun;40(6):3435-3444. doi: 10.21873/anticanres.14329. PMID 32487642